This easy-to-understand, case-based guide explains cancer staging and treatment response assessment using CT/MRI/PET, based on the TNM classification and RECIST/PERCIST.
Using a wealth of sample whole-body radiology reports, this book carefully explains how to conduct integrated imaging diagnosis by combining morphological images (CT, MRI) with functional images (FDG-PET/CT), with a particular focus on the advantages and disadvantages of PET. Based on actual feedback from trainees and novices, this book uses a Q&A format to teach about issues that arise in clinical settings. A must-have for discussions and conferences with clinicians, regardless of whether you're a trainee or a resident!
A practical guide that includes a lymph node atlas to help you understand the differences between cancer classifications and stages and label them appropriately.
[Table of Contents]
Characteristics and Summary of Various Imaging Tests
Abbreviations Used in This Book
Chapter I: Basics of Treatment Response Assessment Using FDG-PET/CT
1 ››› CT Treatment Response Assessment Methods
RECIST, irRECIST, iRECIST: All solid tumors except hepatocellular carcinoma and mesothelioma
EASL, mRECIST, RECICL: Hepatocellular carcinoma
mRECIST: Malignant pleural mesothelioma
Choi Classification: Molecularly targeted drugs for GIST, hepatocellular carcinoma, renal cell carcinoma, etc.
2 ››› PET Quantitative Values
SUVmax, SULpeak, MTV, TLG, etc.
3 ››› PET Treatment Response Assessment Methods
Case Studies Demonstrating the Advantages of FDG-PET/CT
EORTC, PERCIST, imPERCIST: All solid tumors
Lugano Classification, RECIL Classification, LYRIC Classification: Malignant Lymphoma
Chapter II: FDG-PET/CT Diagnosis and Report Examples
1 ››› Fundamentals of FDG-PET/CT Diagnosis and Reporting
10 Important Points
2 ››› Case Presentation and Reporting Practice
1 Pretreatment Staging of Tongue Cancer
2 Pretreatment Staging of Hypopharyngeal Cancer
3 Pretreatment Staging of Lung Cancer
4 Evaluating the Response of Immune Checkpoint Inhibitor Therapy for Lung Cancer ①
5 Evaluating the Response of Immune Checkpoint Inhibitor Therapy for Lung Cancer ②
6 Evaluating the Response of Chemotherapy for Malignant Pleural Mesothelioma
7 Pretreatment Staging of Breast Cancer
8 Diagnosis of Recurrence After Breast Cancer Treatment
9 Evaluating the Response of Preoperative Chemotherapy for Breast Cancer
10 Pretreatment Staging of Esophageal Cancer
11 Pretreatment Staging of Colorectal Cancer
12 Diagnosis of Recurrence After Colorectal Cancer Treatment
13 Evaluating the Response of Molecular Targeted Therapy for Hepatocellular Carcinoma
14 Pretreatment Staging of Cholangiocarcinoma
15 Pretreatment Staging of Pancreatic Cancer
16 Pretreatment Staging of Bladder Cancer
17 Pretreatment Staging of Cervical Cancer
18 Treatment Response Assessment of GIST
19 Pretreatment Staging of Malignant Lymphoma
20 Treatment Response Assessment of Chemotherapy for Malignant Lymphoma
Appendix (Lymph Node Atlas)
